Cytori Therapeutics (NASDAQ: CYTX) this morning said it has received key patents that strengthen its intellectual property portfolio in the U.S. and Europe, sending shares up 2% mid-morning. To date, the company has 107 global patents issued in addition to 45 patent applications pending approval. Many of the most recently issued patents contain claims regarding the use of the company’s Habeo™ Cell Therapy for patients with scleroderma affecting the hands. “Our intellectual property strategy is to continue to strengthen the Cytori Cell Therapy™ platform to help establish and maintain a sustainable competitive advantage. Our main focus is on the primary therapeutic targets of scleroderma and Raynaud’s Phenomenon, though we will continue to seek additional intellectual property in other therapeutic areas as well,” VP and general manager John D. Harris stated in the news release.
To view the full press release, visit: http://nnw.fm/KD4zB
About Cytori
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point¬of¬care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing liposome encapsulated therapies for regenerative medicine and oncologic indications. For more information, please visit www.cytori.com.
View original story at Network News Wire
Read More